A front-of-package food label would be a great educational tool. The Trump administration should keep it.

Piper Sandler analyst Matt O'Brien increased the price target for Glaukos Corporation (NYSE:GKOS) shares to $180 from the previous target of $140, while maintaining an Overweight rating on the stock.

Standing Committee on Public Accounts Chair, Esrom Immanuel says the Judicial Department has four trust fund accounts and the funds have been accumulating over the years. The funds now stands at $45 million which is an increase of $14 million since 2019.

The government is addressing the pressing challenges including poor waterways infrastructure, drainage issues, and underutilized land faced by the people of Drekeniwai Village, Navatu, Cakaudrove.

Many stocks don't offer particularly high yields. The stocks in the S&P 500, for instance, average a yield of just 1.3%. That's not a terribly exciting rate of return on dividends for income investors.

As per the recent earnings update by FactSet dated 24th January 2025, the Q4 2024 earnings season for the S&P 500 has seen a strong start.

DURECT Corporation (Nasdaq: DRRX) today announced the publication of a peer-reviewed article on the AHFIRM trial data in NEJM Evidence. The full article, entitled, "Larsucosterol for the Treatment of Alcohol-Associated Hepatitis,

Corporation (NASDAQ: CTSH) has announced the expansion of its partnership with biopharmaceutical company Gilead Sciences (NASDAQ: NASDAQ:GILD), aiming to enhance Gilead's customer service, employee engagement,

We recently published a list of 10 Unstoppable Stocks to Buy in 2025. In this article, we are going to take a look at where BridgeBio Pharma, Inc.

Delve into the increasingly dynamic landscape of ALS treatment development with thirteen companies advancing candidates in 2025.

Target gave local filmmaker Leonard Searcy a $35,000 grant in October. Searcy was set to meet with the Minneapolis-based retail giant again Thursday to talk about another grant. The company postponed the meeting indefinitely,

PORTLAND, IN, UNITED STATES, January 28, 2025 /EINPresswire / -- The RNA based therapeutics has been explored as a promising treatment option for the diseases which are difficult to treat. Development of this therapeutics is based on promising technologies such as RNA interference technology (RNAi),